Next Article in Journal
Acknowledgment to Reviewers of Psychiatry International in 2021
Previous Article in Journal
Mental Health Symptomatology and Posttraumatic Growth among Those with Multimorbidity in COVID Pandemic: Cross-Sectional Findings from the STRONG Study in Greece
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Psychiatry International
Volume 3
Issue 1
10.3390/psychiatryint3010005
psychiatryint-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Association between Neuroticism and Premenstrual Affective/Psychological Symptomatology

by
Ajna Hamidovic
1,*,
Nhan Dang
2,
Dina Khalil
3 and
Jiehuan Sun
2
1
Department of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Chicago, IL 60612, USA
2
Department of Public Health, University of Illinois at Chicago, 1603 W. Taylor St., Chicago, IL 60612, USA
3
Department of Public Health, Benedictine University, 5700 College Rd., Lisle, IL 60532, USA
*
Author to whom correspondence should be addressed.
Psychiatry Int. 2022, 3(1), 52-64; https://doi.org/10.3390/psychiatryint3010005
Submission received: 24 November 2021 / Revised: 18 January 2022 / Accepted: 21 January 2022 / Published: 26 January 2022
Browse Figure
Review Reports Versions Notes

Abstract

:
Neuroticism and premenstrual conditions share pleiotropic loci and are strongly associated. It is presently not known which DSM-5 symptoms of premenstrual syndrome/premenstrual mood disorder are associated with neuroticism. We enrolled 45 study participants to provide prospective daily ratings of affective (“depression”, “anxiety, “anger”, “mood swings”) and psychological (“low interest”, “feeling overwhelmed”, and “difficulty concentrating”) symptoms across two-three menstrual cycles (128 total cycles). Generalized additive modeling (gam function in R) was implemented to model the relationships between neuroticism and the premenstrual increase in symptomatology. Significance level was adjusted using the False Discovery Rate method and models were adjusted for current age and age of menarche. Results of the association analysis revealed that “low interest” (p ≤ 0.05) and “difficulty concentrating” (p ≤ 0.001) were significantly associated with neuroticism. None of the remaining symptoms reached statistical significance. The late luteal phase of the menstrual cycle is characterized by complex symptomatology, reflecting a physiological milieu of numerous biological processes. By identifying co-expression between neuroticism and specific premenstrual symptomatology, the present study improves our understanding of the premenstrual conditions and provides a platform for individualized treatment developments.

1. Introduction

Given its strong negative emotion basis, neuroticism is considered by some as the single most important factor associated with many forms of psychopathology and behavioral health [1] with important consequences on health and longevity [2,3]. The trait significantly correlates with specific demographic and physiologic characteristics. For example, neuroticism scores tend to be somewhat higher among individuals of lower socioeconomic status [4] and mean neuroticism scores of females are significantly higher than those of males [5]. Moreover, mean neuroticism scores peak in late adolescence and moderately decline in adulthood [6,7,8]. Hence, menarche seems to be a particularly important temporal event, suggestive of a mediatory role of sex hormones on the expression of neuroticism.
This hypothesis is further supported by numerous studies showing an association between premenstrual states/conditions, considered to have an underlying hormonal causality [9], and neuroticism. In an early landmark study, women with high neuroticism were found to be more depressed, irritable, hypersensitive to various stimuli and fatigued during the late luteal (i.e., premenstrual) phase relative to the remaining phases of the menstrual cycle [10]. Later studies found that women with premenstrual syndrome (PMS) [11,12] and premenstrual dysphoric disorder (PMDD) [12,13,14] have higher neuroticism scores compared to healthy controls. Furthermore, PMS/PMDD and neuroticism share pleotropic loci. Investigators of a twin study conducted in Australia examined additive genetic influence on PMS and found a 0.62 genetic correlation between the syndrome and neuroticism scores [15]. To evaluate whether any of the heritable susceptibility to PMDD resides in heritable personality traits, Miller et al. [16] evaluated estrogen-receptor alpha (ESR-1), showing a diagnosis x genotype interaction, with presence of the minor allele of 4 single nucleotide polymorphisms (SNPs), confined to a single locus, in patients, but not healthy controls, associated with high neuroticism.
Presently, PMS/PMDD assessment in The Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) includes an evaluation of 11 core symptoms: (1) mood swings, (2) irritability or anger, (3) depressed mood, (4) anxiety, (5) decreased interest in usual activities, (6) subjective difficulty in concentration, (7) lethargy, (8) change in appetite, overeating, or specific food cravings, (9) hypersomnia or insomnia, (10) a sense of being overwhelmed or out of control, and (11) physical symptoms such as breast tenderness or swelling, joint or muscle pain, a sensation of “bloating,” or weight gain. Items 1 through 4 are considered “affective”, while items 5, 6, and 10, are considered to be “psychological” in nature [17]. Diagnosis of PMDD, according to DSM-5, requires presence of at least one affective symptom to reach the total of 5 (out of the 11 possible) required symptoms, which must be present in most cycles from the past year and confirmed in a prospective manner for at least 2 menstrual cycles. In addition, the symptoms must be associated with clinically significant distress or interference with work, school, usual social activities, or relationship with others. Premenstrual syndrome requires the presence of 1–4 symptoms, without the requirement that one must be affective in nature. Of note, the process of establishing diagnostic criteria for PMS/PMDD has been controversial [18]. It is estimated that approximately 13–18% of women of reproductive age have premenstrual symptoms severe enough to induce impairment and distress, though the number of symptoms may not meet the five symptoms on the PMDD DSM-5 list. Moreover, the DSM-5 does not provide guidance regarding the magnitude of increase in symptomatology required to meet the diagnosis and there is no consensus on how symptom severity should be assessed [18]. Prevalence rates of both PMDD and premenstrual syndrome (PMS) can change dramatically, depending on the method of measuring symptom change [18,19,20]; both PMDD and PMS can be associated with functional impairment [21].
Majority of studies evaluating personality traits in PMS/PMDD relied upon retrospective recall, which conflicts with the current diagnostic standard. For example, Erenoğlu et al. [22] enrolled study participants and assigned the PMS status based on retrospective recall, finding negative correlations between Premenstrual Syndrome Scale (PMSS) scores and several Quick Big Five Personality Test (QBFPT) measures (extraversion, conscientiousness, neuroticism) and a positive correlation between PMSS scores and openness. As neuroticism refers to a predisposition toward experiencing negative affect (e.g., irritability, anxiety) and associated cognitive and behavioral characteristics [23], the negative correlation found in the study by Erenoğlu et al. [22] was the opposite of what would be expected. Indeed, a positive correlation was identified in a prospective study by Ross and colleagues [24], in which study participants completed a Menstrual Distress Questionnaire for 70 days. The researchers found that neuroticism accounted for a significant amount of variation in premenstrual negative affect, measured by the 34-symptom Moss Menstrual Distress Questionnaire.
Personality and PMS/PMDD have shared underlying neurobiological systems [25] and personality can shape how women perceive a given situation, including experiences of PMS/PMDD pathophysiology [26] and recruitment of coping mechanisms [27]. Despite the strong association between PMS/PMDD and neuroticism, it is presently not known which specific DSM-5 symptoms of PMS/PMDD are associated with neuroticism. This understanding has two important implications. First, it identifies neuroticism-based symptom expression in PMS/PMDD, thereby reflecting shared biological mechanisms and providing a greater understanding of PMS/PMDD etiology. This, in turn, expands opportunities for development of future fine-tuned diagnostic and treatment approaches. Second, though still in need of solid evidence and provided that neuroticism marks PMDD [12,28], the trait can be used to estimate the validity of present DSM-5 criteria [28]. In the present study, we implemented a data science approach, which blends aspects of statistical methods, computer science, and machine learning to provide data-driven, efficient exploration of the relationships between variables and optimized prediction of outcomes [29]. We hypothesized that two affective symptoms—irritability/anger and anxiety (DSM items #2 and #4), but not the remaining affective symptoms or psychological PMS/PMDD symptoms—would be associated with neuroticism.

2. Methods

2.1. Study Design

Premenstrual Hormonal and Affective State Evaluation (PHASE) is a single-cohort longitudinal design study with a nested human laboratory between subject experiment. The study enrolls women with regular menstrual cycles to chart their symptoms using the Daily Record of Severity of Problems (DRSP) [30], menstruation timing and ovulation during three menstrual cycles. In the third menstrual cycle, in addition to DRSP collection and LH surge testing, study participants complete: (1) blood and salivary sample collection at 8 different times of the menstrual cycle, and (2) psychosocial stress testing in the late luteal phase. Knowledge gained from PHASE is expected to increase our understanding of menstrual cycle physiology and its dysregulated states. PHASE is a registered clinicaltrials.gov study (NCT03862469).

2.2. Study Sample

Women between the ages of 18 and 35, with regular menstrual cycles lasting 21 to 35 days [31,32,33,34], were recruited from the general population using flyers, word-of-mouth referrals and electronic media (Facebook, Instagram, and Craigslist).
Study participants first completed an online survey, following which they were scheduled to complete an in-person screening. Before any collection of data, study participants signed a consent form, approved by the University of Illinois Human Research Protection Office. Study exclusion criteria were: (a) lifetime DSM-5 Axis I disorder, except anxiety and depression (based on the Structured Clinical Interview for DSM Disorders (SCID)), (b) current (i.e., within the past 12 months) DSM-5 major depressive disorder or an anxiety disorder (based on SCID), (c) positive urine drug screen test, (d) breath alcohol concentration > 0.00%, (e) Alcohol Use Disorders Identification Test (AUDIT) score > 7, (e) self-reported smoker or carbon monoxide concentration ≥ 6 ppm, (f) self-reported irregular menstrual cycle, (g) current pregnancy (urine test-verified) or lactation, or a plan to become pregnant, (h) moderate or high suicide risk, (i) Shipley IQ (vocabulary standard score) < 80, (j) prescription medications, and (k) hormonal contraception.
Race was self-reported by study participants. Reporting race and ethnicity in this study was mandated by the US National Institutes of Health (NIH), consistent with the Inclusion of Women, Minorities, and Children policy. Individuals participating in the poststudy survey were categorized as American Indian or Alaska Native, Asian, Black or African American, Hispanic or Latino, Native Hawaiian or Other Pacific Islander, or White based on the NIH Policy on Reporting Race and Ethnicity Data.
At the screening visit (following eligibility confirmation), study participants completed the Zuckerman–Kuhlman Personality Questionnaire (ZKPQ, Short Version [35]), State-Trait Anxiety Inventory (Y-2) (STAI Y-2 [36]), Becks Depression Inventory (BDI [37]) and Social Adaptation Self-evaluation Scale (SASS [38]. STAI Y-2, BDI and SASS were used to validate our screening procedure, which excluded study participants with DSM-5 Axis I disorders.
Once enrolled and begun their subsequent menstrual cycle, study participants completed DRSP (next section) in REDCap between 7 P.M. and midnight each day for the next three menstrual cycles.

2.3. Study Measures

The Daily Record of Severity of Problems (DRSP) [30] is a validated scale which measures symptoms of PMS/PMDD. Each of the 24 symptoms is rated on a scale of 1 (not at all) to 6 (extreme). The relationship between the 24 DRSP symptoms and the 11 PMDD domains is specified in Table A1. In the present analysis, we evaluated affective and psychological, but not physical, functional, or behavioral symptoms of the questionnaire. This decision was based on the evidence that personality traits are linked to regional differences in brain structure [39,40,41] and function [42,43,44,45,46]. Given the preliminary nature of the present study, we selected affective and psychological symptoms because of their hypothesized closer brain structural and functional proximity to personality traits compared to, for example, physical symptoms of PMS/PMDD. The affective and psychological DSM-5 domains and symptoms, as well as their relation to DRSP questions, evaluated in the present study are listed in Table 1.
Neuroticism was measured using The Zuckerman–Kuhlman Personality Questionnaire (ZKPQ-50-CC) [35] through a self-report questionnaire consisting of 10 true–false statements. The total is calculated by summing up the total number of true statements (each corresponding to 1 point), with 0 reflecting least and 10 reflecting most neuroticism-anxiety. We analyzed neuroticism given the strong association between PMS/PMDD and neuroticism, as discussed in the introduction section.
The Beck Depression Inventory (BDI) [37] is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. Internal consistency for the BDI ranges from 0.73 to 0.92 with a mean of 0.86. [47]. The BDI demonstrates high internal consistency, with alpha coefficients of 0.86 and 0.81 for psychiatric and non-psychiatric populations respectively [48].
The Social Adaptation Self-evaluation Scale (SASS) [38] is a 21-item questionnaire exploring patient motivation and behavior. Each item is scored from 0 to 3 corresponding to no, minimal, medium, and maximum social adjustment. The score range for the SASS total score is, therefore, from 0 to 60. Higher scores signify greater adaptation.
The STAI (Form Y) version [36] contains 20 items which measure state anxiety, and another 20 items which measure trait anxiety. It has been used widely and extensively in research and clinical settings. In the present study, we analyzed the T-Anxiety scale (STAI Form Y-2), which consists of 20 items (item 21 to item 40), measuring how the respondent “generally” feels. The items assess frequency of feeling in general (1 = almost never, 2 = sometimes, 3 = often, and 4 = almost always). Higher scores reflect greater anxiety.

2.4. Data Analysis

For each DRSP symptom, we calculated the degree to which a symptom demonstrated an elevation in days −6 to −1 (“pre-menstruum”) from the start of the cycle relative to days +5 to +10 (“post-menstruum”). This was done for each woman for all available cycles. We subtracted the average post-menstruum score from the average pre-menstruum score and divided this score by participant-specific variance for each symptom. This essentially yielded an effect size for each woman and for each symptom [49].
We next compared neuroticism-anxiety according to diagnosis. Of note, DSM-5 diagnosis is determined as a constellation of affective, psychological, physical, behavioral, and functional symptoms (Table A1) with a “yes” or “no” determination for presence of each symptom. The effect size greater than or equal to 1 reflects presence of a symptom [49] and we applied DSM-5 diagnostic criteria, as described in the “Introduction”. We performed the Kruskal–Wallis rank sum test, with the total neuroticism-anxiety score as the outcome and group (PMDD vs. PMS vs. healthy) as the predictor. We applied Wilcoxon rank sum tests to make pairwise comparisons between group levels with Benjamini–Hochberg corrections for multiple testing.
Our main analysis was to test associations between affective/psychological premenstrual symptoms and neuroticism. Hence, we treated affective and psychological symptoms as continuous variables, reflected as the effect size. The ZKPQ neuroticism-anxiety is measured on a 0–10 scale. We employed 7 separate generalized additive models [29] to study the relationship between neuroticism-anxiety score and each of the 7 affective and psychological symptoms with the total neuroticism score as the predictor and each symptom as the outcome. We adopted “gam” function in the mgcv package in R for fitting the additive models. Specifically, we utilized a spline function for the predictor with maximum degrees of freedom being 6; the best effective degrees of freedom was chosen using generalized cross validation criterion. We first constructed unadjusted models, following which we adjusted the models for current age and current age plus age of menarche based on the literature demonstrating the relationship between duration of ovulatory cycles and premenstrual symptomatology [50]. We used the False Discovery Rate (FDR) method to correct for multiple testing with a p value less than or equal to 0.05 considered significant.

3. Results

3.1. Study Participants

The present study involved 45 participants, approximately 26 years old on average (25.77 ± 4.88 (mean ± SD)). The participant sample was mostly White (33.33%) and Asian (37.78%). For ethnicity, 80% reported non-Hispanic. Approximately half of the participants were currently students, with majority of participants (>90%) reporting the single, never married status and approximately half reporting yearly income less than $20,000. This sample of study participants was on average approximately between normal and overweight BMI status (24.51 (4.45) (mean ± SD)), with the average age of menarche being 12 years old. Please see Table 2 for additional participant characteristic details.
Of the 45 study participants, 7 met the diagnosis for PMDD, 21 met the diagnosis for PMS, and 17 participants were healthy. The diagnosic groups did not differ on the study demographic characteristics (Table A2). The analysis of neuroticism revealed that the PMDD group had higher neuroticism scores relative to the PMS and healthy control (p-adj = 0.028 for both). There was no difference in neuroticism scores between the PMS and healthy control groups. Our methodology of screening out participants with depression or anxiety seemed appropriate according to the results of STAI Y-2, BDI and SASS analyses, which showed normal score means and ranges (Table 2).

3.2. Relationship between Neuroticism-Anxiety and Premenstrual Symptomatology

Of the seven premenstrual symptoms, all except low interest displayed a linear relationship as indicated by estimated degrees of freedom (edf) of 1 (Table 3). Two symptoms (low interest and difficulty concentrating) passed the FDR-adjusted significance level. In the unadjusted models, their significance levels were 0.0392 and 0.0259, respectively. In the fully adjusted models, their significance levels were 0.016275 and 0.0003339, respectively. The highest deviance explained was for difficulty concentrating (48.9%, fully adjusted model), followed by low interest (44.1%, fully adjusted model). Figure 1 displays graphical results of the present analysis.
All models in the present study fully converged. The diagnosis of individual models indicated that the smooths had the sufficient number of basis functions (k value) to capture relationships in the data; that is, the p values were non-significant.

4. Discussion

Results of the present study show that two premenstrual psychological symptoms—low interest and difficulty concentrating—are positively associated with the neuroticism personality trait. Contrary to our hypothesis, irritability/anger and anxiety did not demonstrate a significant association. The remaining affective symptomatology was also not associated with the trait despite the affective symptom requirement in DSM-5 for PMDD diagnosis. Hence, the strong relationship between neuroticism and PMDD does not appear to be mediated by, according to DSM-5, necessary affective symptomatology.
Using stringent, prospective methodology to measure symptomatology, and a validated method to assess personality, the present study highlights co-expression of neuroticism with premenstrual decrease in interest and difficulty concentrating, which are psychological symptoms of PMDD. Our findings do not imply that neuroticism should be considered in the diagnosis criteria. Rather, the study identifies neuroticism-based symptom expression in PMS/PMDD, thereby reflecting shared biological mechanisms and expanding opportunities for development of future clinical approaches.
DSM-5 and research findings [21] emphasize high prevalence of impairment in PMS/PMDD and emphasize impairment as a metric for determining clinical significance of premenstrual symptoms. Schmalenberger et al. [17] sought to clarify symptoms that best predict three types of premenstrual impairment types (occupational, relational and recreational). The group found that affective, psychological, and physical symptoms differ in their associations with impairment. Psychological symptoms of PMS/PMDD predicted all three types of functional impairment, while affective symptoms predicted recreational and relational, but not occupational, impairment. Hence, psychological symptoms modulate functionality in a more comprehensive fashion than affective symptoms, and, as in the present study, these results highlight the importance of considering psychological symptoms in PMS/PMDD.
Anhedonia is a critical symptom of mood disorders. It predominantly manifests emotionally as a lack of feeling pleasure, as well as reduced motivation and drive on the behavioral level [51]. It is a significant predictor of psychosocial functioning [52]. In an attempt to identify the mechanisms underlying the varied symptoms associated with depression, Liao et al. [53] assessed two dimensions of Major Depressive Disorder (MDD)—anxiety and anhedonia—in relation to neuroticism, finding significant associations between neuroticism and each symptom. A critical difference between MDD and PMDD is the temporal nature of symptom expression in PMDD, as the transition between affective states, or the “switch”, in PMDD is confined to the late luteal phase of menstrual cycle, presenting a clue to its hormonal causality [9]. Results of our study, therefore, suggest that the relationship between low drive/interest and neuroticism appears to have a hormonal basis, while the relationship between anxiety and neuroticism does not, as MDD is not considered a disorder caused by shifting sex hormones (or their metabolites). Our findings, however, will need to be replicated in a study involving a larger sample size.
In addition to finding a significant relationship between low interest and the neuroticism trait, our study also revealed a significant association between premenstrual difficulty in concentrating and neuroticism. Indeed, several cognitive deficits are associated with high levels of neuroticism, including cognitive decline [54], inefficient cognitive performance [55], and increased risk of Alzheimer’s disease [56,57]. Inefficient cognitive processing in neuroticism was found to be, in part, due to elevated ‘‘mental noise’’ caused by preoccupations with intrusive thoughts and distress [55,58]. We show that women of reproductive age, who experience self-reported cognitive difficulties specifically in the late luteal phase of the menstrual cycle, also score high on neuroticism. A study evaluating interactions between neuroticism, shifting levels of hormones across the menstrual cycle and cognitive control is a critical future research area, with significant clinical implications.
A limitation of our study is the sample size of 45 participants. Although our analytic approach appropriately corrected for multiple comparisons, the present analysis ideally should be replicated in a larger sample size. We were not able to evaluate all DRSP items corresponding to a particular affective symptom (Table A1). For example, affective lability could be operationalized as mood swings, feeling suddenly sad or tearful, or increased sensitivity to rejection, which represent different DRSP items. To limit the number of comparisons, while being consistent in our approach, we always selected the first item on the list of affective symptoms. For example, for affective lability, we analyzed only mood swings, but not increased sensitivity to rejection. Moreover, DSM-5 specifies that premenstrual symptom increase must be “marked”, without defining what this means clinically. We applied the analytical method of calculating effect size (i.e., symptom increase) from Hartlage et al. [49], which specifies that a 100% increase in premenstrual symptomatology is clinically relevant. However, this method does not necessitate that study participants were marking their symptoms as very severe (for example, 5 or 6 on the DRSP Likert scale). A strength of our study is the prospective nature of symptom collection and an adjustment for follicular phase symptomatology, which isolates symptom exacerbation specifically in the late luteal phase of the menstrual cycle. Moreover, we measured symptoms from days −6 to −1 from the start of the subsequent menstrual cycles, which removes a possible reporting bias due to knowledge of the actual start of the period (i.e., vaginal bleeding) if the symptom measurement was, for example, from days −5 to +1, or −4 to +2. Our analysis both adjusted for multiple comparisons and important covariates.
Clarifying associations between premenstrual symptoms and neuroticism can improve the use of novel therapeutics. The present study improves our understanding of PMS/PMDD etiology, as it identified co-expression of neuroticism and hormonally-mediated exacerbation of psychological symptoms (low interest and difficulty concentrating). This can inform drug development and non-pharmacologic treatment approaches, thereby improving care for patients suffering from debilitating premenstrual symptomatology.

Author Contributions

A.H., Conceptualization, Writing—original draft, Formal analysis, Funding acquisition, Methodology, Supervision, Writing—review and editing; N.D., Formal analysis, Validation, D.K., Project administration, Resources, Writing—review and editing; J.S., Formal analysis, Validation. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by National Institute of Mental Health/National Institutes of Health, grant number R21MH119642.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of The Office for the Protection of Research Subjects (OPRS) at University of Illinois at Chicago, approval number 2018-1533.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Acknowledgments

We would like to thank the participants who provided the data for this research study.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Appendix A

Table
Table A1. Domain type and symptoms of PMDD as specified in DSM-5.
Table A1. Domain type and symptoms of PMDD as specified in DSM-5.
DSM-5 SymptomsDRSP QuestionInclusion in Present Analysis
1. Marked affective lability (e.g., mood swings, feeling suddenly sad or tearful, or increased sensitivity to rejection *,#5. Had mood swings (e.g., suddenly felt sad or tearful)
DRSP 6. Was more sensitive to rejection
or my feelings were easily hurt		Included as affective symptom
2. Marked irritability or anger or increased interpersonal conflicts *,#7. Felt angry, irritable
8. Had conflicts or problems with
people		Included as affective symptom
3. Marked depressed mood, feelings of hopelessness, or self-deprecating thoughts *,#1. Felt depressed, sad, down, or blue
2. Felt hopeless
3. Felt worthless or guilty		Included as affective symptom
4. Marked anxiety, tension, and/or feelings of being keyed up or on edge *,#4. Felt anxious, tense, keyed up, or on edgeIncluded as affective symptom
5. Decreased interest in usual activities (e.g., work, school, friends, hobbies)9. Had less interest in usual activities (e.g., work, school, friends, hobbies)Included as psychological symptom
6. Subjective difficulty in concentration10. Had difficulty concentratingIncluded as psychological symptom
7. A sense of being overwhelmed or out of control #16. Felt overwhelmed or that I could not cope
17. Felt out of control		Included as psychological symptom
8. Marked change in appetite; overeating; or specific food cravings12. Had increased appetite or overate
13. Had cravings for specific foods		Not included—behavioral symptom
9. Hypersomnia or insomnia14. Slept more, took naps, found it hard to get up when intended
15. Had trouble getting to sleep or staying asleep		Not included—behavioral symptom
10. Lethargy, easy fatigability, or marked lack of energy11. Felt lethargic, tired, fatigued, or had a lack of energyNot included—physical symptom
11. One physical symptom (for example, breast tenderness)18. Had breast tenderness
19. Had breast swelling, felt bloated, or had weight gain
20. Had headache
21. Had joint or muscle pain		Not included—physical symptom
* At least one symptom from items 1 to 4 in column 1 (DSM-5 Symptoms) be present for PMDD diagnosis. # Only first symptom inside the parentheses was included in the analysis.
Table
Table A2. Demographic characteristics according to diagnosis.
Table A2. Demographic characteristics according to diagnosis.
Demographic
Variable		CategoryDiagnostic Categoryp Value
PMDD (n = 7)PMS (n = 21)Healthy (n = 17)
Age 25.1 (3.89)25 (5.34)27 (4.68)0.27
RaceWhite0.070.130.130.77
Black or African American0.020.070.09
American Indian or Alaska Native000
Asian0.040.220.11
Native Hawaiian or
Other Pacific Islander		000
More than one race0.0200.02
Unknown/Do not want to specify00.040.02
EthnicityHispanic0.020.070.070.52
Non-Hispanic0.110.400.29
Unknown/Do not want to specify0.0200.02
Student
Status		Yes0.090.200.130.61
No0.070.270.24
Marital
Status		Single0.160.420.330.99
Married00.040.04
Divorced000
Widowed000
IncomeLess than $20,0000.090.330.130.08
$20,000–$34,9990.0200.11
$35,000–$49,9990.020.040.04
$50,000–$74,9990.020.040.09
75,000 or more00.040
Age of Menarche 12.4 (1.14)12.1 (0.93)11.7 (1.41)0.21
BMI 24.0 (3.25)24.9 (5.45)24.3 (3.73)0.99

References

  1. Ormel, J.; Jeronimus, B.F.; Kotov, R.; Riese, H.; Bos, E.H.; Hankin, B.; Rosmalen, J.G.; Oldehinkel, A.J. Neuroticism and common mental disorders: Meaning and utility of a complex relationship. Clin. Psychol. Rev. 2013, 33, 686–697. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Friedman, H.S. Neuroticism and health as individuals age. Personal. Disord. Theory Res. Treat. 2019, 10, 25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Eysenck, H.J. Intelligence assessment: A theoretical and experimental approach. Br. J. Educ. Psychol. 1967, 37, 81–98. [Google Scholar] [CrossRef] [PubMed]
  4. Judge, T.A.; Higgins, C.A.; Thoresen, C.J.; Barrick, M.R. The Big Five personality traits, general mental ability, and career success across the life span. Pers. Psychol. 1999, 52, 621–652. [Google Scholar] [CrossRef]
  5. Costa, P.T.; Terracciano, A.; McCrae, R.R. Gender differences in personality traits across cultures: Robust and surprising findings. J. Personal. Soc. Psychol. 2001, 81, 322–331. [Google Scholar] [CrossRef]
  6. Costa Jr, P.T.; McCrae, R.R.; Zonderman, A.B.; Barbano, H.E.; Lebowitz, B.; Larson, D.M. Cross-sectional studies of personality in a national sample: II. Stability in neuroticism, extraversion, and openness. Psychol. Aging 1986, 1, 144. [Google Scholar] [CrossRef]
  7. McCrae, R.R.; Costa, P.T.; Terracciano, A.; Parker, W.D.; Mills, C.J.; De Fruyt, F.; Mervielde, I. Personality trait development from age 12 to age 18: Longitudinal, cross-sectional, and cross-cultural analyses. J. Personal. Soc. Psychol. 2002, 83, 1456–1468. [Google Scholar] [CrossRef]
  8. Roberts, B.W.; Mroczek, D. Personality trait change in adulthood. Curr. Dir. Psychol. Sci. 2008, 17, 31–35. [Google Scholar] [CrossRef] [Green Version]
  9. Schmidt, P.J.; Martinez, P.E.; Nieman, L.K.; Koziol, D.E.; Thompson, K.D.; Schenkel, L.; Wakim, P.G.; Rubinow, D.R. Premenstrual dysphoric disorder symptoms following ovarian suppression: Triggered by change in ovarian steroid levels but not continuous stable levels. Am. J. Psychiatry 2017, 174, 980–989. [Google Scholar] [CrossRef]
  10. Benedek, T.; Rubenstein, B.B. The correlations between ovarian activity and psycho-dynamic processes. II. The menstrual phase. Psychosom. Med. 1939, 1, 461–485. [Google Scholar] [CrossRef]
  11. Arslantaş, H.; Abacigil, F.; Çinakli, Ş. Relationship between premenstrual syndrome and basic personality traits: A cross-sectional study. Sao Paulo Med. J. 2018, 136, 339–345. [Google Scholar] [CrossRef] [PubMed]
  12. del Mar Fernández, M.; Regueira-Méndez, C.; Takkouche, B. Psychological factors and premenstrual syndrome: A Spanish case-control study. PLoS ONE 2019, 14, e0212557. [Google Scholar] [CrossRef] [PubMed]
  13. Gingnell, M.; Comasco, E.; Oreland, L.; Fredrikson, M.; Sundström-Poromaa, I. Neuroticism-related personality traits are related to symptom severity in patients with premenstrual dysphoric disorder and to the serotonin transporter gene-linked polymorphism 5-HTTPLPR. Arch. Women’s Ment. Health 2010, 13, 417–423. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Adewuya, A.; Loto, O.; Adewumi, T. Premenstrual dysphoric disorder amongst Nigerian university students: Prevalence, comorbid conditions, and correlates. Arch. Women’s Ment. Health 2008, 11, 13–18. [Google Scholar] [CrossRef]
  15. Treloar, S.A.; Heath, A.; Martin, N. Genetic and environmental influences on premenstrual symptoms in an Australian twin sample. Psychol. Med. 2002, 32, 25–38. [Google Scholar] [CrossRef]
  16. Miller, A.; Vo, H.; Huo, L.; Roca, C.; Schmidt, P.J.; Rubinow, D.R. Estrogen receptor alpha (ESR-1) associations with psychological traits in women with PMDD and controls. J. Psychiatr. Res. 2010, 44, 788–794. [Google Scholar] [CrossRef] [Green Version]
  17. Schmalenberger, K.M.; Eisenlohr-Moul, T.A.; Surana, P.; Rubinow, D.R.; Girdler, S.S. Predictors of premenstrual impairment among women undergoing prospective assessment for premenstrual dysphoric disorder: A cycle-level analysis. Psychol. Med. 2017, 47, 1585–1596. [Google Scholar] [CrossRef] [Green Version]
  18. Halbreich, U.; Borenstein, J.; Pearlstein, T.; Kahn, L.S. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003, 28, 1–23. [Google Scholar] [CrossRef]
  19. Gehlert, S.; Hartlage, S. A design for studying the DSM-IV research criteria of premenstrual dysphoric disorder. J. Psychosom. Obstet. Gynecol. 1997, 18, 36–44. [Google Scholar] [CrossRef]
  20. Robinson, R.L.; Swindle, R.W. Premenstrual symptom severity: Impact on social functioning and treatment-seeking behaviors. J. Women’s Health Gend.-Based Med. 2000, 9, 757–768. [Google Scholar] [CrossRef]
  21. Freeman, E.W. Premenstrual syndrome and premenstrual dysphoric disorder: Definitions and diagnosis. Psychoneuroendocrinology 2003, 28, 25–37. [Google Scholar] [CrossRef]
  22. Erenoğlu, R.; Sözbir, Ş.Y. Are premenstrual syndrome and dysmenorrhea related to the personality structure of women? A descriptive relation-seeker type study. Perspect. Psychiatr. Care 2020, 56, 979–984. [Google Scholar] [CrossRef] [PubMed]
  23. Costa, P.T., Jr.; McCrae, R.R. Four ways five factors are basic. Personal. Individ. Differ. 1992, 13, 653–665. [Google Scholar] [CrossRef]
  24. Ross, C.; Coleman, G.; Stojanovska, C. Relationship between the NEO personality inventory revised neuroticism scale and prospectively reported negative affect across the menstrual cycle. J. Psychosom. Obstet. Gynecol. 2001, 22, 165–176. [Google Scholar] [CrossRef] [PubMed]
  25. Gao, M.; Qiao, M.; An, L.; Wang, G.; Wang, J.; Song, C.; Wei, F.; Yu, Y.; Gong, T.; Gao, D. Brain reactivity to emotional stimuli in women with premenstrual dysphoric disorder and related personality characteristics. Aging 2021, 13, 19529–19541. [Google Scholar] [CrossRef]
  26. Magnus, K.; Diener, E.; Fujita, F.; Pavot, W. Extraversion and neuroticism as predictors of objective life events: A longitudinal analysis. J. Personal. Soc. Psychol. 1993, 65, 1046. [Google Scholar] [CrossRef]
  27. Strutton, D.; Pelton, L.E.; Lumpkin, J.R. Personality characteristics and salespeople’s choice of coping strategies. J. Acad. Mark. Sci. 1995, 23, 132–140. [Google Scholar] [CrossRef]
  28. Aperribai, L.; Alonso-Arbiol, I.; Balluerka, N.; Claes, L. Development of a screening instrument to assess premenstrual dysphoric disorder as conceptualized in DSM-5. J. Psychosom. Res. 2016, 88, 15–20. [Google Scholar] [CrossRef] [Green Version]
  29. Hastie, T.J.; Tibshirani, R.J. Generalized Additive Models; Routledge: London, UK, 2017. [Google Scholar]
  30. Endicott, J.; Nee, J.; Harrison, W. Daily Record of Severity of Problems (DRSP): Reliability and validity. Arch. Women’s Ment. Health 2006, 9, 41–49. [Google Scholar] [CrossRef]
  31. Gingnell, M.; Bannbers, E.; Wikstrom, J.; Fredrikson, M.; Sundstrom-Poromaa, I. Premenstrual dysphoric disorder and prefrontal reactivity during anticipation of emotional stimuli. Eur. Neuropsychopharmacol. 2013, 23, 1474–1483. [Google Scholar] [CrossRef]
  32. Deng, D.; Pang, Y.; Duan, G.; Liu, H.; Liao, H.; Liu, P.; Liu, Y.; Li, S.; Chen, W.; Wen, D.; et al. Larger volume and different functional connectivity of the amygdala in women with premenstrual syndrome. Eur. Radiol. 2018, 28, 1900–1908. [Google Scholar] [CrossRef] [PubMed]
  33. Solis-Ortiz, S.; Corsi-Cabrera, M. Sustained attention is favored by progesterone during early luteal phase and visuo-spatial memory by estrogens during ovulatory phase in young women. Psychoneuroendocrinology 2008, 33, 989–998. [Google Scholar] [CrossRef] [PubMed]
  34. Sohda, S.; Suzuki, K.; Igari, I. Relationship between the menstrual cycle and timing of ovulation revealed by new protocols: Analysis of data from a self-tracking health app. J. Med. Internet Res. 2017, 19, e391. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Aluja, A.; Rossier, J.; García, L.F.; Angleitner, A.; Kuhlman, M.; Zuckerman, M. A cross-cultural shortened form of the ZKPQ (ZKPQ-50-cc) adapted to English, French, German, and Spanish languages. Personal. Individ. Differ. 2006, 41, 619–628. [Google Scholar] [CrossRef]
  36. Spielberger, C.D. State-Trait Anxiety Inventory for Adults. 1983. Available online: https://psycnet.apa.org/doi/10.1037/t06496-000 (accessed on 1 September 2021).
  37. Beck, A.T.; Ward, C.; Mendelson, M.; Mock, J.; Erbaugh, J. Beck depression inventory (BDI). Arch. Gen. Psychiatry 1961, 4, 561–571. [Google Scholar] [CrossRef] [Green Version]
  38. Bosc, M.; Dubini, A.; Polin, V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur. Neuropsychopharmacol. 1997, 7, S57–S70. [Google Scholar] [CrossRef]
  39. Omura, K.; Constable, R.T.; Canli, T. Amygdala gray matter concentration is associated with extraversion and neuroticism. Neuroreport 2005, 16, 1905–1908. [Google Scholar] [CrossRef]
  40. Wright, C.I.; Williams, D.; Feczko, E.; Barrett, L.F.; Dickerson, B.C.; Schwartz, C.E.; Wedig, M.M. Neuroanatomical correlates of extraversion and neuroticism. Cereb. Cortex 2006, 16, 1809–1819. [Google Scholar] [CrossRef] [Green Version]
  41. Sollberger, M.; Stanley, C.M.; Wilson, S.M.; Gyurak, A.; Beckman, V.; Growdon, M.; Jang, J.; Weiner, M.W.; Miller, B.L.; Rankin, K.P. Neural basis of interpersonal traits in neurodegenerative diseases. Neuropsychologia 2009, 47, 2812–2827. [Google Scholar] [CrossRef] [Green Version]
  42. Adelstein, J.S.; Shehzad, Z.; Mennes, M.; DeYoung, C.G.; Zuo, X.-N.; Kelly, C.; Margulies, D.S.; Bloomfield, A.; Gray, J.R.; Castellanos, F.X. Personality is reflected in the brain’s intrinsic functional architecture. PLoS ONE 2011, 6, e27633. [Google Scholar] [CrossRef]
  43. Tran, Y.; Craig, A.; Boord, P.; Connell, K.; Cooper, N.; Gordon, E. Personality traits and its association with resting regional brain activity. Int. J. Psychophysiol. 2006, 60, 215–224. [Google Scholar] [CrossRef] [PubMed]
  44. Jaušovec, N.; Jaušovec, K. Personality, gender and brain oscillations. Int. J. Psychophysiol. 2007, 66, 215–224. [Google Scholar] [CrossRef] [PubMed]
  45. Sutin, A.R.; Beason-Held, L.L.; Resnick, S.M.; Costa, P.T. Sex differences in resting-state neural correlates of openness to experience among older adults. Cereb. Cortex 2009, 19, 2797–2802. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Sheng, T.; Gheytanchi, A.; Aziz-Zadeh, L. Default network deactivations are correlated with psychopathic personality traits. PLoS ONE 2010, 5, e12611. [Google Scholar] [CrossRef] [PubMed]
  47. Beck, A.T.; Steer, R. Überblick über Reliabilitäts-und Validitätsbefunde von klinischen und außerklinischen Selbst-und Fremdbeurteilungsverfahren. J. Consult. Clin. Psychol. 1988, 56, 893–897. [Google Scholar] [CrossRef] [PubMed]
  48. Beck, A.T.; Epstein, N.; Brown, G.; Steer, R.A. An inventory for measuring clinical anxiety: Psychometric properties. J. Consult. Clin. Psychol. 1988, 56, 893. [Google Scholar] [CrossRef]
  49. Hartlage, S.A.; Freels, S.; Gotman, N.; Yonkers, K. Criteria for Premenstrual Dysphoric Disorder Secondary Analyses of Relevant Data Sets. Arch. Gen. Psychiatry 2012, 69, 300–305. [Google Scholar] [CrossRef] [Green Version]
  50. Dennerstein, L.; Lehert, P.; Bäckström, T.C.; Heinemann, K. Premenstrual symptoms—Severity, duration and typology: An international cross-sectional study. Menopause Int. 2009, 15, 120–126. [Google Scholar] [CrossRef]
  51. Watson, R.; Harvey, K.; McCabe, C.; Reynolds, S. Understanding anhedonia: A qualitative study exploring loss of interest and pleasure in adolescent depression. Eur. Child Adolesc. Psychiatry 2020, 29, 489–499. [Google Scholar] [CrossRef] [Green Version]
  52. Vinckier, F.; Gourion, D.; Mouchabac, S. Anhedonia predicts poor psychosocial functioning: Results from a large cohort of patients treated for major depressive disorder by general practitioners. Eur. Psychiatry 2017, 44, 1–8. [Google Scholar] [CrossRef]
  53. Liao, Y.; Xie, B.; Zhang, H.; He, Q.; Guo, L.; Subramaniapillai, M.; Fan, B.; Lu, C.; Mclntyer, R. Efficacy of omega-3 PUFAs in depression: A meta-analysis. Transl. Psychiatry 2019, 9, 190. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Wilson, R.S.; Bennett, D.A.; de Leon, C.F.M.; Bienias, J.L.; Morris, M.C.; Evans, D.A. Distress proneness and cognitive decline in a population of older persons. Psychoneuroendocrinology 2005, 30, 11–17. [Google Scholar] [CrossRef] [PubMed]
  55. Robinson, M.D.; Tamir, M. Neuroticism as mental noise: A relation between neuroticism and reaction time standard deviations. J. Personal. Soc. Psychol. 2005, 89, 107. [Google Scholar] [CrossRef] [PubMed]
  56. Duchek, J.M.; Balota, D.A.; Storandt, M.; Larsen, R. The power of personality in discriminating between healthy aging and early-stage Alzheimer’s disease. J. Gerontol. Ser. B Psychol. Sci. Soc. Sci. 2007, 62, P353–P361. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Wilson, R.S.; Arnold, S.E.; Schneider, J.A.; Li, Y.; Bennett, D.A. Chronic distress, age-related neuropathology, and late-life dementia. Psychosom. Med. 2007, 69, 47–53. [Google Scholar] [CrossRef] [PubMed]
  58. Munoz, E.; Sliwinski, M.J.; Smyth, J.M.; Almeida, D.M.; King, H.A. Intrusive thoughts mediate the association between neuroticism and cognitive function. Personal. Individ. Differ. 2013, 55, 898–903. [Google Scholar] [CrossRef] [Green Version]
Psychiatryint 03 00005 g001 550
Figure 1. Graphical presentation of Generalized Additive Modeling (GAM) for the Neuroticism-Anxiety Personality Trait in Relation to Premenstrual Symptoms. Psychological symptoms “low interest” and “difficulty concentrating” were significantly associated with neuroticism.
Figure 1. Graphical presentation of Generalized Additive Modeling (GAM) for the Neuroticism-Anxiety Personality Trait in Relation to Premenstrual Symptoms. Psychological symptoms “low interest” and “difficulty concentrating” were significantly associated with neuroticism.
Psychiatryint 03 00005 g001
Table
Table 1. Domain type and symptoms of PMS/PMDD as specified in DSM-5 in relation to DRSP Questions.
Table 1. Domain type and symptoms of PMS/PMDD as specified in DSM-5 in relation to DRSP Questions.
DomainDSM-5 SymptomsDRSP Question
AffectiveMarked affective lability (e.g., mood swings; feeling suddenly sad or tearful, or increased sensitivity to rejection)DRSP 5. Had mood swings (e.g., suddenly
felt sad or tearful)
Marked irritability or anger or
increased interpersonal conflicts		DRSP 7. Felt angry, irritable
Marked depressed mood, feelings of
hopelessness, or self-deprecating thoughts		DRSP 1. Felt depressed, sad, ‘down’ or
blue
Marked anxiety, tension, and/or
feelings of being keyed up or on edge		DRSP 4. Felt anxious, ‘keyed up’, or ‘on
edge’
PsychologicalDecreased interest in usual activities
(e.g., work, school, friends, hobbies)		DRSP 9. Had less interest in usual
activities (e.g., work, school, friends,
hobbies)
Subjective difficulty in concentrationDRSP 10. Had difficulty concentrating
A sense of being overwhelmed or out of controlDRSP 16. Felt overwhelmed, that I
couldn’t cope
Table
Table 2. Demographic, Anthropomorphic and Psychological Characteristics of Study Participants.
Table 2. Demographic, Anthropomorphic and Psychological Characteristics of Study Participants.
VariableMean (SD)Percent
AGE25.77 (4.88)
RACE
 White 33.33
 Black or African American 17.78
 American Indian/Alaska Native 0.00
 Asian 37.78
 Native Hawaiian or Other Pacific Islander 0.00
 More than one race 4.44
 Unknown/do not want to specify 6.67
ETHNICITY
 Hispanic 15.55
 Non-Hispanic 80.00
 Do not know/Do not want to specify 4.44
STUDENT STATUS
 Yes 42.22
 No 57.78
MARITAL STATUS
 Single, never married 91.11
 Married 8.89
INCOME
 Less than $20,000 55.56
 $20,000–$34,999 13.33
 $35,000–$49,999 11.11
 $50,000–$74,999 15.56
 $75,000 or more 4.44
AGE OF MENACHE12.03 (1.11)
BMI24.51 (4.45)
BECKS DEPRESSION INVENTORY (BDI)4.27 (5.14)
SOCIAL ADAPTATION SELF EVALUATION SCALE (SASS)46.70 (6.19)
STATE TRAIT ANXIETY INVENTORY (Y-2)36.37 (7.85)
Table
Table 3. Results of General Additive Modeling (GAM) for the Neuroticism-Anxiety Personality Trait in Relation to Premenstrual Symptoms.
Table 3. Results of General Additive Modeling (GAM) for the Neuroticism-Anxiety Personality Trait in Relation to Premenstrual Symptoms.
Premenstrual SymptomUnadjusted ModelModel Adjusted for AgeModel Adjusted for Age and Age of Menarche
EdfDeviance ExplainedFp-Adjusted *EdfDeviance ExplainedFp-Adjusted *EdfDeviance ExplainedFp-Adjusted *
Affective Lability17.24%3.3550.1722110.7%3.7420.1393121%5.0810.07536667
Irritability/Anger14.64%2.0920.21717.9%2.3520.166833119.2%4.3990.079275
Depression13.92%1.7540.22417.65%2.2320.166833114.2%2.5460.1708
Anxiety10.0232%0.9210.92112.91%0.0730.78917.95%0.550.465
Low Interest2.04423.4%4.3510.0392 *1.71824.1%4.9690.034195 *2.27744.1%5.3580.016275 *
Difficulty Concentrating117.9%9.3940.0259 *124.4%12.060.00826 *148.9%22.620.0003339 *
Feeling Overwhelmed15.89%2.6930.18918.07%2.4370.166833112.9%2.0990.1855
* p values adjusted for multiple comparisons using false discovery rate (FDR).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Hamidovic, A.; Dang, N.; Khalil, D.; Sun, J. Association between Neuroticism and Premenstrual Affective/Psychological Symptomatology. Psychiatry Int. 2022, 3, 52-64. https://doi.org/10.3390/psychiatryint3010005

AMA Style

Hamidovic A, Dang N, Khalil D, Sun J. Association between Neuroticism and Premenstrual Affective/Psychological Symptomatology. Psychiatry International. 2022; 3(1):52-64. https://doi.org/10.3390/psychiatryint3010005

Chicago/Turabian Style

Hamidovic, Ajna, Nhan Dang, Dina Khalil, and Jiehuan Sun. 2022. "Association between Neuroticism and Premenstrual Affective/Psychological Symptomatology" Psychiatry International 3, no. 1: 52-64. https://doi.org/10.3390/psychiatryint3010005

Article Metrics

Back to TopTop